



To Advocate For Justice And Victims' Rights  
With Integrity, Passion And Excellence.

### Latest News For You



### Allergan Class Action

Late last year, we began talking with a number of women about their concerns with their breast implants, manufactured by Allergan and marketed under the brand

BIOCELL, some of which are also known as “gummy breast implants.”

Allergan recalled the textured implants and tissue expanders in 2019 after disclosures that those with the implants suffered a six-fold increase in a specific type of cancer called breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).

While we at FeganScott were concerned with the underlying health risks, we were also shocked at Allergan’s behavior in working with the thousands of women who have the implants and tissue expanders.

When we originally filed the case, we claimed that Allergan refused to care for, monitor, or compensate people who seek to remove the recalled implants or undergo invasive and expensive diagnostic procedures.

As the case progressed and more women expressed their concern about the implants, we filed an expanded 1,300-page complaint that names 62 plaintiffs, which broadened the range of the allegedly defective products covered by the suit and ensured representative coverage for all people with the implants and tissue expanders nationwide.

We have also been fighting Allergan’s attempt to extract releases of liability from women with the recalled products in exchange for payments between \$1,000-\$7,500. When promising these payments, Allergan did not tell class members that signing the release would mean giving up their ability to make any claims against the company in the event they later developed BIA-ALCL, or their ability to take part in any benefits that may result from our ongoing class litigation. Based on our efforts, the Court recently ordered that corrective notice must be given to all women who signed the releases so that they can challenge them.

We believe that Allergan’s attempt to extract releases without providing full disclosure of their effect is deceptive – and want to ensure that women who want to have their implants removed or receive diagnostic testing and monitoring to guard against developing cancer have that option.

Looking ahead, we are currently opposing Allergan’s legal arguments that plaintiffs’ claims are preempted and are engaged in the early stages of discovery.

If you or someone you know might be interested in learning more about this case, we invite you to share this communication with them and encourage you to reach out to our firm today.

Additionally, if you believe you received this communication in error, we honor unsubscribe requests immediately.

[Contact Us To Learn More](#)

[See All News](#)

---

## Related Cases You Might Be Interested In




Roundup Class Action

[Learn More](#)



Apple Smartphone Class Action

[Learn More](#)



Zantac Class Action

[Learn More](#)

[Our Firm](#)

[Current Cases](#)

[Successes](#)

[Investigation](#)

[Who We Serve](#)

 **feganscott**

150 S. Wacker Dr., 24th Floor  
Chicago, IL 60606  
844-399-5171 | 630-273-2625

[Contact Us](#)

